MedTrace Logo

PK and PD of YG1699 in CKD Patients With Diabetes

NCT06648876 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2024-10-18

No results posted yet for this study

Summary

The goal of this clinical trial is to learn PK and PD of YG1699 in patients with diabetes and renal dysfuction.

Participants will:

Take YG1699 or a placebo every day for 8 days. Visit the clinic 7 times for checkups and tests. Keep a diary of their symptoms. Estimate PK data from a single dose of YG1699. Estimate PD data at baseline and the last day.

Conditions

  • Diabetes
  • Renal Insufficiency, Chronic
  • Hemodialysis

Interventions

DRUG

YG1699

10mg qd for 8 days

DRUG

Placebo

10mg qd for 8 days

Sponsors & Collaborators

  • RenJi Hospital

    lead OTHER

Principal Investigators

  • Leyi Gu · RenJi Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-10-31
Primary Completion
2025-08-31
Completion
2025-10-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06648876 on ClinicalTrials.gov